In another research, HHT has been shown to possess a synergistic or additive effect with imatinib against a BCR–ABL+ cell line with an imatinib-resistant E255K mutation and cells from patients with CML in blastic phase (BP) [98, 99]. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.